Martin Shkreli insider trades: Kalobios Pharmaceuticals (KBIO) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Martin reports to the SEC
Open-market buys and sales
40 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 26, 2016 | KBIO | ↓ Sell | 2,222,929 | $3.10 | $6.9M | Direct | Aug 29, 2016 (3d) |
| Nov 24, 2015 | KBIO | ↑ Buy | 5,000 | $38.15 | $191K | Direct | Nov 24, 2015 (0d) |
| Nov 20, 2015 | KBIO | ↑ Buy | 5,000 | $18.88 | $94K | Direct | Nov 23, 2015 (3d) |
| Nov 18, 2015 | KBIO | ↑ Buy | 440,000 | $2.02 | $889K | Direct | Nov 19, 2015 (1d) |
| Nov 17, 2015 | KBIO | ↑ Buy | 1,211,115 | $1.35 | $1.6M | Direct | Nov 18, 2015 (1d) |
| Nov 21, 2014 | RTRX | ↓ Sell | 1,172,000 | $8.84 | $10.4M | Direct | Nov 24, 2014 (3d) |
| Oct 1, 2014 | RTRX | ↑ Buy | 25,000 | $8.11 | $203K | Direct | Oct 9, 2014 (8d) |
| Oct 1, 2014 | RTRX | ↓ Sell | 300,000 | $0.01 | $3K | Direct | Oct 9, 2014 (8d) |
| Sep 30, 2014 | RTRX | ↑ Buy | 4,000 | $9.42 | $38K | Direct | Oct 2, 2014 (2d) |
| Sep 22, 2014 | RTRX | ↑ Buy | 53,000 | $11.15 | $591K | Direct | Sep 23, 2014 (1d) |
| Sep 17, 2014 | RTRX | ↑ Buy | 6,000 | $11.46 | $69K | Direct | Sep 18, 2014 (1d) |
| Sep 16, 2014 | RTRX | ↑ Buy | 7,500 | $10.69 | $80K | Direct | Sep 16, 2014 (0d) |
| May 30, 2014 | RTRX | ↓ Sell | 292,400 | $15.14 | $4.4M | Direct | Jun 3, 2014 (4d) |
| Apr 4, 2014 | RTRX | ↑ Buy | 8,000 | $19.64 | $157K | Direct | Apr 7, 2014 (3d) |
| Apr 3, 2014 | RTRX | ↑ Buy | 22,500 | $22.60 | $508K | Direct | Apr 4, 2014 (1d) |
| Apr 2, 2014 | RTRX | ↑ Buy | 10,800 | $22.28 | $241K | Direct | Apr 3, 2014 (1d) |
| Mar 24, 2014 | RTRX | ↑ Buy | 4,000 | $17.61 | $70K | Direct | Mar 27, 2014 (3d) |
| Mar 20, 2014 | RTRX | ↑ Buy | 5,000 | $17.97 | $90K | Direct | Mar 21, 2014 (1d) |
| Mar 19, 2014 | RTRX | ↑ Buy | 3,500 | $18.44 | $65K | Direct | Mar 20, 2014 (1d) |
| Mar 14, 2014 | RTRX | ↑ Buy | 4,000 | $17.36 | $69K | Direct | Mar 17, 2014 (3d) |
| Mar 11, 2014 | RTRX | ↑ Buy | 25,900 | $19.47 | $504K | Direct | Mar 12, 2014 (1d) |
| Mar 10, 2014 | RTRX | ↑ Buy | 10,700 | $19.32 | $207K | Direct | Mar 11, 2014 (1d) |
| Mar 7, 2014 | RTRX | ↑ Buy | 4,058 | $18.52 | $75K | Direct | Mar 10, 2014 (3d) |
| Mar 5, 2014 | RTRX | ↑ Buy | 4,000 | $18.48 | $74K | Direct | Mar 6, 2014 (1d) |
| Feb 28, 2014 | RTRX | ↑ Buy | 43,100 | $18.66 | $804K | Direct | Mar 3, 2014 (3d) |
| Feb 21, 2014 | RTRX | ↑ Buy | 1,600 | $17.56 | $28K | Direct | Feb 25, 2014 (4d) |
| Feb 14, 2014 | RTRX | ↑ Buy | 3,500 | $14.60 | $51K | Direct | Feb 19, 2014 (5d) |
| Feb 6, 2014 | RTRX | ↑ Buy | 2,000 | $9.92 | $20K | Direct | Feb 7, 2014 (1d) |
| Jan 14, 2014 | RTRX | ↑ Buy | 8,000 | $10.84 | $87K | Direct | Jan 15, 2014 (1d) |
| Dec 31, 2013 | RTRX | ↑ Buy | 150,000 | $7.00 | $1.1M | Direct | Jan 2, 2014 (2d) |
| Dec 9, 2013 | RTRX | ↑ Buy | 200 | $8.21 | $2K | Direct | Dec 10, 2013 (1d) |
| Nov 26, 2013 | RTRX | ↑ Buy | 450 | $6.31 | $3K | Direct | Dec 2, 2013 (6d) |
| Sep 12, 2013 | RTRX | ↑ Buy | 11,112 | $4.50 | $50K | Direct | Sep 16, 2013 (4d) |
| Aug 22, 2013 | RTRX | ↑ Buy | 3,900 | $6.06 | $24K | Direct | Aug 23, 2013 (1d) |
| Mar 11, 2013 | RTRX | ↑ Buy | 500 | $4.61 | $2K | Direct | Mar 12, 2013 (1d) |
| Mar 4, 2013 | RTRX | ↑ Buy | 1,000 | $4.42 | $4K | Direct | Mar 6, 2013 (2d) |
| Feb 20, 2013 | RTRX | ↑ Buy | 1,120 | $4.16 | $5K | Direct | Feb 21, 2013 (1d) |
| Feb 14, 2013 | RTRX | ↑ Buy | 120,000 | $3.00 | $360K | Direct | Feb 19, 2013 (5d) |
| Feb 12, 2013 | RTRX | ↑ Buy | 1,400 | $3.57 | $5K | Direct | Feb 13, 2013 (1d) |
| Dec 26, 2012 | RTRX | ↑ Buy | 200 | $5.62 | $1K | Direct | Dec 28, 2012 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Martin Shkreli's insider trades
Martin Shkreli is a 10% owner of Kalobios Pharmaceuticals (KBIO). Since Dec 26, 2012, Martin has reported 36 open-market purchases worth $8.3M and 4 sales worth $21.7M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include other transactions (6 filings), grants and awards (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KBIO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.